Premium
NXY‐059 Does Not Significantly Interact With Furosemide in Healthy Volunteers
Author(s) -
Strid Stig,
Nilsson Dag,
Borgå Olof,
Wemer Johan,
Grahnén Anders
Publication year - 2006
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006293372
Subject(s) - furosemide , medicine , pharmacology
NXY‐059 is a free radical—trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. Acute ischemic stroke patients receiving NXY‐059 may also be exposed to diuretics for treatment of heart failure or hypertension. NXY‐059 and furosemide are partly eliminated by active tubular secretion via an organic anion transporter. This double‐blind, randomized, crossover, placebo‐controlled study investigated whether an infusion of NXY‐059 (15 mg/mL) during 12 hours affects the diuretic and saluretic effects of a 30‐mg intravenous bolus dose of furosemide (10 mg/mL) administered after 6 hours' infusion, in 13 male and 11 female healthy subjects. The net increase in urine volume and sodium excretion in the interval of 6 to 12 hours was 4.15 L and 178 mmol/L, respectively, during NXY‐059 treatment ( P = .93) and 4.34 L and 190 mmol/L, respectively, during placebo treatment ( P = .54). NXY‐059 reduced the renal clearance of furosemide by 19% ( P = .019), and furosemide reduced the renal clearance of NXY‐059 by 8% ( P = .005). NXY‐059 was well tolerated.